Sartorius Stedim Biotech SA: Half-year report of the liquidity contract with the stockbroker company Gilbert Dupont

Aubagne, France, July 2, 2020

Half-year report of the liquidity contract with the stockbroker company Gilbert Dupont

Under the liquidity contract concluded between SARTORIUS STEDIM BIOTECH and the stockbroker Gilbert Dupont, the following assets appeared on the liquidity account on June 30, 2020:

• Number of shares: 1,941
• Liquidity account cash balance: €591,334.56

During the first half of 2020, the following were negotiated:

It should be noted that in the second half of 2019, which ended December 31, 2019, the following assets appeared on the liquidity account:

• Number of shares: 3,225
• Liquidity account cash balance: €370,692.66

It should also be noted that upon implementing the liquidity contract, the following assets were made available:

• Number of shares: 654
• Liquidity account cash balance: €394,895.12

A profile of Sartorius Stedim Biotech

Sartorius Stedim Biotech is a leading international partner of the biopharmaceutical industry. As a total solutions provider, the company helps its customers to manufacture biotech medications safely, rapidly and economically. Headquartered in Aubagne, France, Sartorius Stedim Biotech is quoted on the Eurolist of Euronext Paris. With its own manufacturing and R&D sites in Europe, North America and Asia and an international network of sales companies, Sartorius Stedim Biotech has a global reach. The Group has been annually growing by double digits on average and has been regularly expanding its portfolio by acquisitions of complementary technologies. In 2019, the company employed approx. 6,200 people, and earned sales revenue of €1,440.6 million.

Contact

Ben Orzelek

Head of Investor Relations

+49 (0)551.308.1668

[email protected]

Sartorius Stedim Biotech S.A.

Z.I. Les Paluds

Avenue de Jouques, CS 91051

13781 Aubagne Cedex, France

Phone: +33.(0)4.42.84.56.00

Fax: +33.(0)4.42.84.56.19

www.sartorius-stedim.com